Scioderm Names Ronald Nardi, Ph.D. Chief Scientific Officer

Scioderm Names Ronald Nardi, Ph.D. Chief Scientific Officer

DURHAM, N.C., June 12, 2014 /PRNewswire/ -- Scioderm, Inc. today announced the addition of Ronald Nardi, Ph.D. as the company's first chief scientific officer.

Key points:

Dr. Nardi brings more than 35 years of experience in drug discovery, development and regulatory affairs and was most recently the executive vice president of regulatory affairs and quality assurance at International Partnership for Microbicides.
Dr. Nardi was previously the chief scientific officer for Ferring Pharmaceuticals A/S and later for BioValve Technologies, Inc. and has been instrumental in obtaining regulatory approvals for a number of medical devices and novel therapeutics.
He also has R&D operational and management experience with Wyeth Pharmaceuticals, GlaxoSmithKline and Warner-Lambert Company.
Dr. Nardi received his Ph.D. in pharmacology and toxicology from Rutgers University and completed a postdoctoral fellowship at the Institute for Cancer Research at Fox Chase Cancer Center.
Quotes:

Robert Ryan, Ph.D., president and chief executive officer of Scioderm said, "Ron's depth of experience in therapeutic target identification, clinical drug development and regulatory registration filing, as well as his superb reputation in scientific research, make him an excellent addition to Scioderm's leadership team.

Ronald Nardi, chief scientific officer of Scioderm said, "Scioderm is at the leading edge of developing treatments for epidermolysis bullosa and I have closely followed the development of SD-101. As there currently is no FDA approved treatment for epidermolysis bullosa, SD-101 could fill an urgent need and I am proud to join a team committed to developing novel therapies."

About Epidermolysis Bullosa (EB)

Epidermolysis Bullosa (EB) is a rare genetic connective tissue disorder, with many genetic and symptomatic variations. All forms of EB share the common symptom of fragile skin that blisters and tears from the slightest friction or trauma. This particular manifestation has led to EB patients being known as "butterfly children" due to the analogous nature of the fragility of the skin to the wings of a butterfly. As of today there is no cure or effective treatment. The more severe forms of the disease lead to scarring, disfigurement, disability and early death, usually before the age of 30.

About Scioderm, Inc.

Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address diseases with critical unmet medical needs, including orphan products. Scioderm was the first biotech to receive "Breakthrough Therapy" designation for SD-101 from the Food and Drug Administration (FDA) for the treatment of skin effects in patients with EB. The company is headquartered in Durham, North Carolina. Additional information about Scioderm can be found at www.sderm.com.

Forward Looking Statement

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Scioderm disclaims any intent or obligation to update these forward-looking statements.

Scioderm Investor Contact:

Robert Coull
Chief Operating Officer
(919)-824-2594
[email protected]

Scioderm Media Contacts:

Andrea Flynn, Ph.D.
Russo Partners LLC
(646) 942-5631
[email protected]

Julia Jackson
Cooney/Waters Group
(212) 886-2249
[email protected]

SOURCE Scioderm, Inc.

Suggested Articles

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.